(Q37732148)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

review article

1 reference

title

Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Lawrence D Ginsberg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

12 Suppl 12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

8-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression.

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

The P revention of R ecurrent E pisodes of Depression with Ven lafaxine for T wo Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Which factors influence psychiatrists' selection of antidepressants?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Incidence and Duration of Side Effects and Those Rated as Bothersome With Selective Serotonin Reuptake Inhibitor Treatment for Depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Continuity is the main challenge in treating major depressive disorder in psychiatric care.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Prevalence of sexual dysfunction among newer antidepressants.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Tolerability and safety of fluvoxamine and other antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Effects of SSRIs on sexual function: a critical review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

SSRI Antidepressant Medications: Adverse Effects and Tolerability

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026353

7 January 2021

10.1017/S1092852900026353

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20397586%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference